Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Non-Current Deffered Revenue (2020 - 2022)

Historic Non-Current Deffered Revenue for Lyell Immunopharma (LYEL) over the last 3 years, with Q3 2022 value amounting to $37.2 million.

  • Lyell Immunopharma's Non-Current Deffered Revenue fell 5461.45% to $37.2 million in Q3 2022 from the same period last year, while for Sep 2022 it was $37.2 million, marking a year-over-year decrease of 5461.45%. This contributed to the annual value of $79.7 million for FY2021, which is 1055.51% down from last year.
  • Lyell Immunopharma's Non-Current Deffered Revenue amounted to $37.2 million in Q3 2022, which was down 5461.45% from $32.9 million recorded in Q2 2022.
  • Over the past 5 years, Lyell Immunopharma's Non-Current Deffered Revenue peaked at $89.1 million during Q4 2020, and registered a low of $32.9 million during Q2 2022.
  • Over the past 3 years, Lyell Immunopharma's median Non-Current Deffered Revenue value was $79.7 million (recorded in 2021), while the average stood at $68.6 million.
  • Per our database at Business Quant, Lyell Immunopharma's Non-Current Deffered Revenue plummeted by 1055.51% in 2021 and then plummeted by 5978.53% in 2022.
  • Over the past 3 years, Lyell Immunopharma's Non-Current Deffered Revenue (Quarter) stood at $89.1 million in 2020, then fell by 10.56% to $79.7 million in 2021, then plummeted by 53.35% to $37.2 million in 2022.
  • Its Non-Current Deffered Revenue stands at $37.2 million for Q3 2022, versus $32.9 million for Q2 2022 and $77.9 million for Q1 2022.